![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, May 30, 2018 11:45:49 AM
HERE IS THE COMPLETE MT. SINAI ARTICLE
Investigational Device Shows Potential for Treating Immune Dysregulation Disorders
A recent case at Mount Sinai Beth Israel suggests that an investigational device may have potential benefits as a life- saving therapy for nephrology, immunology, and hematology patients with immune dysregulation disorders.
Nikolas Harbord, MD, an Assistant Professor of Medicine (Nephrology) at the Icahn School of Medicine at Mount Sinai, saw a 39-year-old male who presented with fever, dyspnea, and lymphadenopathy. An extensive malignancy and infection workup followed, including biopsies of bone marrow, lymph nodes, and liver, resulting in a diagnosis of hemophagocytic lymphohistiocytosis (HLH), an often deadly disease that is diagnosed in one out of every 800,000 people annually but may be undiagnosed in many more.
Recognizing that the patient had a relatively poor prognosis, the nephrology and intensive care team obtained institutional review board approval for compassionate use of CytoSorb® to treat the patient. Manufactured by the CytoSorbents Corporation in New Jersey, CytoSorb is an extracorporeal cytokine adsorber approved for use in Europe in situations where cytokines are elevated, such as systematic inflammatory response syndrome, sepsis, liver failure, and post-cardiac surgery. It is not currently FDA approved.
“One of our emeritus faculty is an expert in hemoperfusion and sorbent technology and a consultant for CytoSorbents,” Dr. Harbord says. “We knew based on that experience that it could help, so we received institutional permission to use the device, and the company sent it to us.”
The patient was started on a daily six-hour regimen of combined hemodialysis/hemoperfusion, which was performed by a dialysis nurse. After the patient’s blood was cleaned through dialysis, it was passed through the CytoSorb device, where biocompatible porous polymer beads removed the cytokines. Dr. Harbord says the patient’s clinical improvement was immediate and significant, with hemodynamic stabilization during the first treatment, followed by enhanced liver function and mental status.
“We were able to demonstrate marked improvement in the patient’s clinical illness by removing the cytokines, which were responsible for his hypotension and shock,” Dr. Harbord says. “The dose of pressors,
the day-to-day bloodwork—all of it improved, and we saw a 56 percent reduction in cytokines over the course of therapy.”
Dr. Harbord says that CytoSorb is nonspecific, removing many elevated cytokines (both pro- and anti-inflammatory), but he adds that the risks are not significant and that the risk of not intervening may be greater. Given the results achieved in this investigational use, he says, cytokine hemadsorption has potential as a treatment for HLH, a disease with a mortality rate in excess of 50 percent.
“I think we demonstrated real proof-of-concept benefit for patients through investigational use,” Dr. Harbord says. “I would not hesitate to use it again, and I would hope it gives other nephrologists the confidence to adopt it based on our experience at Mount Sinai.”
Recent CTSO News
- CytoSorbents Secures $20 Million Credit Facility • GlobeNewswire Inc. • 07/02/2024 11:00:00 AM
- CytoSorbents Announces Regulatory Approval of CytoSorb® in Taiwan • GlobeNewswire Inc. • 06/24/2024 11:00:00 AM
- CytoSorbents Announces the Launch and Immediate Availability of the PuriFi™ Blood Pump in the European Union • GlobeNewswire Inc. • 06/13/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 08:31:20 PM
- CytoSorbents to Host its 2024 Virtual Annual Stockholders Meeting • GlobeNewswire Inc. • 06/05/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2024 08:35:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 09:23:00 PM
- CytoSorbents Reports First Quarter 2024 Results • GlobeNewswire Inc. • 05/09/2024 08:17:23 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:14:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 09:00:30 PM
- CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe • GlobeNewswire Inc. • 05/02/2024 11:00:00 AM
- CytoSorbents to Report First Quarter 2024 Operating and Financial Results • GlobeNewswire Inc. • 04/26/2024 11:00:00 AM
- STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting • GlobeNewswire Inc. • 04/17/2024 11:00:00 AM
- CytoSorbents to Report Fiscal 2023 Operating and Financial Results • GlobeNewswire Inc. • 03/06/2024 12:00:00 PM
- CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/08/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 10:20:45 PM
- Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients • GlobeNewswire Inc. • 01/17/2024 12:15:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/08/2024 08:00:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:49:02 PM
- CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation • GlobeNewswire Inc. • 12/28/2023 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:35:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:34:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:34:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:33:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:32:55 PM
Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • BLO • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM